Topical superoxide dismutase reduces post‐irradiation breast cancer fibrosis

Fibrosis following breast radiotherapy for mammary cancer is a frequent undesired effect with objective (esthetic) and subjective (pain) consequences. Forty‐four patients with clinical radiofibrosis following conservative treatment of breast cancer were evaluated for the local antifibrosis effect of copper zinc superoxide dismutase [SOD(Cu/Zn)]. Extracted SOD(Cu/Zn) in a concentration of 3,600 units/mg was applied as ointment to the fibrotic affected area, b.i.d. for 90 days, in a total dose of 40 mg. The radiofibrosis intensity was scored on the basis of clinical criteria (pain and the fibrosis area) before and after SOD(Cu/Zn) treatment. SOD(Cu/Zn) was found to be effective in reducing radiation induced fibrosis by a lowering pain score in 36/39 patients and a decrease of the fibrotic area size in half cases, after 6 months. The intensity and changes of breast fibrosis were assessed also by mammography and, for the topographical distribution of subcutaneous temperature, by infrared thermography. Mammography density suggested decreased fibrosis in one third of patients. Thermography showed that fibrosis was accompanied by two zones clinically indistinctive: a central area with maximum thermal activity, called “Maximal Thermic zone” (MTZ) and a peripheral area with less thermal activity but higher than in the surrounding normal tissue, “Transitional Thermic Zone” (TTZ). Both MTZ and TTZ were significantly decreased in 36/44 patients after SOD(Cu/Zn) treatment. Clinical changes persisted all along the study. Treatment was well tolerated except for one case of local allergic reaction, and no important side effects. Molecular mechanisms involved are discussed. Further studies are running to confirm and explain these results.

[1]  W. Huber Orgotein--(bovine Cu-Zn superoxide dismutase), an anti-inflammatory protein drug: discovery, toxicology and pharmacology. , 1981, European journal of rheumatology and inflammation.

[2]  O. S. Nielsen,et al.  Orgotein in radiation treatment of bladder cancer. A report on allergic reactions and lack of radioprotective effect. , 1987, Acta oncologica.

[3]  Anna Niwin¯ska,et al.  Cosmetic evaluation of breast conserving treatment for mammary cancer , 1998 .

[4]  S. Batra,et al.  Lipid peroxidation, free radical production and antioxidant status in breast cancer , 2004, Breast Cancer Research and Treatment.

[5]  O. S. Nielsen,et al.  Lack of radiation protective effect of orgotein in normal and malignant mammalian cells. , 1979, Acta radiologica: oncology, radiation, physics, biology.

[6]  E. E. Vogin,et al.  Safety tests of orgotein, an antiinflammatory protein. , 1973, Toxicology and applied pharmacology.

[7]  H. Cramer,et al.  Radioprotective effect of free radical scavenging enzymes. , 1990, The Journal of otolaryngology.

[8]  I. Turesson Individual variation and dose dependency in the progression rate of skin telangiectasia. , 1990, International journal of radiation oncology, biology, physics.

[9]  John A. Tainer,et al.  Structure and mechanism of copper, zinc superoxide dismutase , 1983, Nature.

[10]  N. Robert,et al.  Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Martin,et al.  Abnormal phenotype of cultured fibroblasts in human skin with chronic radiotherapy damage. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  M. Monte,et al.  [Free radicals of oxygen and superoxide dismutase. Biological and medical aspects]. , 1994, Medicina.

[13]  G. Lorette,et al.  Lésions cutanées induites par la radiothérapie: prévention, traitements , 2001 .

[14]  R. Mehvar Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. , 2000, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[15]  A. Hart,et al.  Dose and volume effects on fibrosis after breast conservation therapy. , 1994, International journal of radiation oncology, biology, physics.

[16]  E van der Schueren,et al.  Cosmetic evaluation of breast conserving treatment for mammary cancer. 2. A quantitative analysis of the influence of radiation dose, fractionation schedules and surgical treatment techniques on cosmetic results. , 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  H. Duan,et al.  MnSOD up-regulates maspin tumor suppressor gene expression in human breast and prostate cancer cells. , 2003, Antioxidants & redox signaling.

[18]  H. Iwase,et al.  [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[19]  A. Brahme,et al.  Principles and Practice of Radiation Oncology , 1992 .

[20]  I. Andrulis,et al.  Genetic Variants of GPX1 and SOD2 and Breast Cancer Risk at the Ontario Site of the Breast Cancer Family Registry , 2004, Cancer Epidemiology Biomarkers & Prevention.

[21]  A. Petkau,et al.  Radioprotection by superoxide dismutase of macrophage progenitor cells from mouse bone marrow. , 1984, Biochemical and biophysical research communications.

[22]  I. Fridovich,et al.  A direct demonstration of the catalytic action of superoxide dismutase through the use of pulse radiolysis. , 1972, The Journal of biological chemistry.

[23]  P. Schlienger,et al.  Conservative management of operable breast cancer. Ten years experience at the Foundation Curie , 1978, Cancer.

[24]  L. Machet,et al.  [Radiation-induced skin toxicities: prevention, treatment]. , 2001, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[25]  H. Magdelenat,et al.  Effects of superoxide dismutase topical treatment on human skin radiofibrosis: a pathological study , 1996 .

[26]  J. McCord,et al.  Free Radicals as Mediators of Tissue Injury , 1980 .

[27]  F. Baillet,et al.  [Action of liposomal superoxide dismutase on measurable radiation-induced fibrosis]. , 1989, Annales de medecine interne.

[28]  S Hellman,et al.  The effect of adjuvant chemotherapy on the cosmetic results after primary radiation treatment for early stage breast cancer. , 1984, International journal of radiation oncology, biology, physics.

[29]  S. Kharb,et al.  Serum biochemical markers in carcinoma breast. , 2003, Indian journal of medical sciences.

[30]  F. Baillet,et al.  Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: clinical trial. , 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[31]  A. Petkau Scientific basis for the clinical use of superoxide dismutase. , 1986, Cancer treatment reviews.

[32]  I. Fentiman,et al.  Assessment of skin dose and its relation to cosmesis in the conservative treatment of early breast cancer. , 1988, International journal of radiation oncology, biology, physics.

[33]  F. Holmes,et al.  Consequences of breast irradiation in patients with pre-existing collagen vascular diseases. , 1989, International journal of radiation oncology, biology, physics.

[34]  I. Turesson,et al.  The influence of fraction size in radiotherapy on the late normal tissue reaction--I: Comparison of the effects of daily and once-a-week fractionation on human skin. , 1984, International journal of radiation oncology, biology, physics.